U.SIntravenous Solution Market, by Solution Type (Saline (Normal saline 0.9%NaCl and Hypertonic saline), Dextran (D5W 5% dextrose in water and AnalogHypertonic Saline), Lactated Ringer’s, Amino Acid, Vitamins & Minerals,Heparin and trace elements, and Mixed Solutions), By Packaging (Ampules, Vials,Cartridges, Bottles, Bags (Large Volume Bags-greater than 250ml and SmallVolume Bags-less than 250ml), By Indication (Oncology, Post-Operative Care,General Medicine, Burn Management, Pulmonary Disorders, CardiovascularDiseases, and Others), and By End User (Hospitals, Clinics, Ambulatory SurgicalCenters, Home care Settings, and Others) is estimated to be valued at US$2,811.3 million in 2021 and is expected to exhibit a CAGR of 6.1% during theforecast period (2021-2028), as highlighted in a new report published byCoherent Market Insights.
U.S Intravenous Solutions Market-Impact of Coronavirus (COVID-19) Pandemic
Lockdown in various countries dueto the pandemic has placed an economic burden on the private healthcare sector.Healthcare providers are facing challenges with regards to decliningoutpatient’s visits, manpower, equipment, consumables, and other resources toensure safety in treatment of patients with other diseases. The global COVID-19pandemic has sharply focused the attention of the world onto critical care ofCOVID-19 patients. During the early stages of the COVID-19 pandemic, it was acommon advice of physicians to aim for a negative fluid balance. Nowadays, ahigher occurrence of acute kidney injury requiring renal replacement therapyhas been observed, prompting for a more liberal fluid strategy. For instance,the World Health Organization guidelines recommend that patients with COVID-19in respiratory failure should be treated cautiously with intravenous fluids,especially in settings with limited availability of mechanical ventilation.
Use a conservative fluidmanagement strategy for acute respiratory distress syndrome (ARDS) patientswithout tissue hypoperfusion
In resuscitation for septic shockin adults, give 250–500 mL crystalloid fluid as a rapid bolus in the first15–30 minutes and reassess for signs of fluid overload after each bolus
Consider dynamic indices ofvolume responsiveness to guide volume administration beyond initialresuscitation based on local resources and experience. These indices includepassive leg raises, fluid challenges with serial stroke volume measurements, orvariations in systolic pressure, pulse pressure, inferior vena cava size, orstroke volume in response to changes in intrathoracic pressure duringmechanical ventilation.
Thus, due to lockdown anddisruption in supply chain and the increasing demand of healthcare products forpatients, this pandemic has hampered the U.S intravenous solution market.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3400
However, the increasing number ofproduct approvals from regulatory bodies, collaborations and partnershipstrategies adopted by key players are some of the major factors which areexpected to drive growth of the U.S intravenous solution market during theforecast period. For instance, in November 2016, Mallinckrodt Pharmaceuticalsreceived U.S. Food and Drug Administration’s (FDA) Prior Approval Supplementfor its OFIRMEV (acetaminophen) injection (new drug application) available inan intravenous (IV) bag presentation.
Administration of IV fluids inthe patients of cardiac arrhythmia helps in improvement of haemodynamic statusin critically ill patients. Thus, the increasing number prevalence of cardiacarrhythmia is expected to provide huge opportunities to the U.S intravenoussolution market growth in the near future. For instance, the Centers forDisease Control and Prevention 2014, estimated that 2.7–6.1 million people inthe U.S. suffered from atrial fibrillation. With increasing aging population,this number is also expected to increase.
The increasing number of patientadmissions in ambulatory surgical centers for surgical procedures, whichrequires intravenous solutions or infusion for administration of drugs isexpected to drive the ambulatory surgical centers (ASCs) segment growth. Forinstance, according to the H-Cup Journal Report 2017, in the U.S., there werearound 17.2 million ambulatory hospital visits recorded in the hospitals.
A person suffering from diarrheaalso suffers from intense fluid loss and dehydration. Thus, diarrhea patientsare highly prescribed with IV fluids such as saline and vitamins. Increasingprevalence of diarrhea is expected to drive growth of U.S intravenous solutionmarket during the forecast period. For instance, according to the articlepublished in New England Journal of Medicine, April 2014, 179 million cases ofacute diarrhea are registered annually in the U.S.
Browse 13 Market Data Tables and40 Figures spread through 169 Pages and in-depth TOC on U.S IntravenousSolution Market, by Solution Type (Saline (Normal saline 0.9% NaCl andHypertonic saline), Dextran (D5W 5% dextrose in water and Analog HypertonicSaline), Lactated Ringer’s, Amino Acid, Vitamins & Minerals, Heparin andtrace elements, and Mixed Solutions), By Packaging (Ampules, Vials, Cartridges,Bottles, Bags (Large Volume Bags-greater than 250ml and Small Volume Bags-lessthan 250ml), By Indication (Oncology, Post-Operative Care, General Medicine,Burn Management, Pulmonary Disorders, Cardiovascular Diseases, and Others), andBy End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home careSettings, and Others) - Forecast to 2028"
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/us-intravenous-solution-market-3400
The increasing number ofsurgeries are expected to propel demand for large volume of Intravenous (IV)solutions. For instance, according to Healthcare Cost and Utilization Projectreport 2020, a total of 17.2 million hospital visits (as visits or inpatientstays) in the United States included at least one surgery in 2017.
Key Takeaways of the U.SIntravenous Solution Market:
The U.S intravenous solutionmarket is expected to exhibit a CAGR of 6.1% during the forecast period(2021-2028) owing to the increasing launches of new intravenous solutioninjections for the treatment of various issues such as neuromuscular blockadeand paralysis, this is expected to boost the market growth over the forecastperiod. For instance, in 2017, Fresenius Kabi USA, LLC, a provider of medicinesand technologies for infusion, transfusion, and clinical nutrition, launchedVecuronium Bromide IV injection in the U.S. The drug is indicated formaintenance of neuromuscular blockade and paralysis.
Among solution type, Salinesegment is expected to hold major revenue share in 2028, owing to theincreasing incidence of gastroenteritis, which is expected to contribute to thegrowth of the saline segment. For instance, according to the data of NationalCenter of Biotechnology Information 2020, acute viral gastroenteritis accountsfor 19 to 21 million cases of diarrheal illnesses annually in the U.S.
Major players operating in theU.S intravenous solution market are B. Braun Melsungen AG., BaxterInternational Inc., Fresenius Kabi USA, LLC, Grifols, S.A., JW Life Science,Amanta Healthcare, Salius Pharma Private Limited, Axa Parenterals Ltd., ViforPharma Management Ltd., ICU Medical, Inc., and Pfizer Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3400
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200 Seattle,WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
